Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Recommendation of “Buy” from Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have been given a consensus recommendation of “Buy” by the nine research firms that are presently covering the firm, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $15.97.

VYGR has been the topic of several research reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. Wedbush initiated coverage on shares of Voyager Therapeutics in a report on Friday, November 29th. They issued an “outperform” rating and a $11.00 price objective on the stock. Cantor Fitzgerald initiated coverage on shares of Voyager Therapeutics in a report on Friday. They issued an “overweight” rating and a $5.73 price objective on the stock. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Leerink Partners initiated coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective on the stock.

Voyager Therapeutics Trading Down 4.9 %

Shares of VYGR opened at $5.45 on Friday. The company has a market cap of $297.71 million, a price-to-earnings ratio of 7.68 and a beta of 0.93. Voyager Therapeutics has a 1-year low of $5.19 and a 1-year high of $10.66. The company’s fifty day simple moving average is $6.13 and its 200 day simple moving average is $6.84.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. The business had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period in the previous year, the company earned ($0.59) earnings per share. As a group, research analysts forecast that Voyager Therapeutics will post -0.89 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the sale, the chief operating officer now owns 112,328 shares of the company’s stock, valued at $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 4.53% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Voyager Therapeutics by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after acquiring an additional 4,098 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of Voyager Therapeutics in the third quarter worth about $74,000. Victory Capital Management Inc. lifted its holdings in shares of Voyager Therapeutics by 14.5% in the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after acquiring an additional 1,630 shares during the last quarter. Hsbc Holdings PLC bought a new position in shares of Voyager Therapeutics in the second quarter worth about $128,000. Finally, Verition Fund Management LLC bought a new position in shares of Voyager Therapeutics in the third quarter worth about $216,000. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.